Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay

P. Katz, A. M. Zaytoun, A. S. Fauci

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

This study investigated the defective natural killer (NK) cell activity in 2 patients with the Chediak-Higashi syndrome (CHS), using both a standard 51-chromium release microcytotoxicity and a single cell-in-agarose assay against K562 and Molt-4 target cells. CHS patients were deficient in overall maximum NK capacity, but had normal percentages of potentially cytotoxic target binding cells. The relative number of TBC that could kill bound targets (i.e., 'active' NK cells) was significantly depressed in CHS patients when compared with normal controls. The diminished CHS active NK cells that were present, however, were capable of recycling and lysing multiple target cells during the assay period. In vitro interferon (INF) treatment of normal and CHS effector cells did not alter target cell binding, but did increase the maximum NK capacity, percentage of active NK cells, and the maximum recycling capacity, as well as the rate of lysis. These studies indicate that the depression of NK activity in patients with CHS is secondary to a deficiency of active NK cells. The CHS active NK cells that are present, however, are capable of normal target lysis and recycling. Potentially cytotoxic pre-NK cells, which can bind but not kill target cells, can be activated by in vitro IFN to develop lytic activity. Thus, IFN treatment may be of potential benefit to the immune surveillance network of CHS patients by activating a population of pre-NK cells to express their cytotoxic potential.

Original languageEnglish
Pages (from-to)1231-1238
Number of pages8
JournalJournal of Clinical Investigation
Volume69
Issue number6
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Chediak-Higashi Syndrome
Natural Killer Cells
Recycling
Population Growth
Chromium
Sepharose
Interferons

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. / Katz, P.; Zaytoun, A. M.; Fauci, A. S.

In: Journal of Clinical Investigation, Vol. 69, No. 6, 01.01.1982, p. 1231-1238.

Research output: Contribution to journalArticle

@article{8cd150a190aa4fcbb5ee5cd51acb94f0,
title = "Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay",
abstract = "This study investigated the defective natural killer (NK) cell activity in 2 patients with the Chediak-Higashi syndrome (CHS), using both a standard 51-chromium release microcytotoxicity and a single cell-in-agarose assay against K562 and Molt-4 target cells. CHS patients were deficient in overall maximum NK capacity, but had normal percentages of potentially cytotoxic target binding cells. The relative number of TBC that could kill bound targets (i.e., 'active' NK cells) was significantly depressed in CHS patients when compared with normal controls. The diminished CHS active NK cells that were present, however, were capable of recycling and lysing multiple target cells during the assay period. In vitro interferon (INF) treatment of normal and CHS effector cells did not alter target cell binding, but did increase the maximum NK capacity, percentage of active NK cells, and the maximum recycling capacity, as well as the rate of lysis. These studies indicate that the depression of NK activity in patients with CHS is secondary to a deficiency of active NK cells. The CHS active NK cells that are present, however, are capable of normal target lysis and recycling. Potentially cytotoxic pre-NK cells, which can bind but not kill target cells, can be activated by in vitro IFN to develop lytic activity. Thus, IFN treatment may be of potential benefit to the immune surveillance network of CHS patients by activating a population of pre-NK cells to express their cytotoxic potential.",
author = "P. Katz and Zaytoun, {A. M.} and Fauci, {A. S.}",
year = "1982",
month = "1",
day = "1",
language = "English",
volume = "69",
pages = "1231--1238",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay

AU - Katz, P.

AU - Zaytoun, A. M.

AU - Fauci, A. S.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - This study investigated the defective natural killer (NK) cell activity in 2 patients with the Chediak-Higashi syndrome (CHS), using both a standard 51-chromium release microcytotoxicity and a single cell-in-agarose assay against K562 and Molt-4 target cells. CHS patients were deficient in overall maximum NK capacity, but had normal percentages of potentially cytotoxic target binding cells. The relative number of TBC that could kill bound targets (i.e., 'active' NK cells) was significantly depressed in CHS patients when compared with normal controls. The diminished CHS active NK cells that were present, however, were capable of recycling and lysing multiple target cells during the assay period. In vitro interferon (INF) treatment of normal and CHS effector cells did not alter target cell binding, but did increase the maximum NK capacity, percentage of active NK cells, and the maximum recycling capacity, as well as the rate of lysis. These studies indicate that the depression of NK activity in patients with CHS is secondary to a deficiency of active NK cells. The CHS active NK cells that are present, however, are capable of normal target lysis and recycling. Potentially cytotoxic pre-NK cells, which can bind but not kill target cells, can be activated by in vitro IFN to develop lytic activity. Thus, IFN treatment may be of potential benefit to the immune surveillance network of CHS patients by activating a population of pre-NK cells to express their cytotoxic potential.

AB - This study investigated the defective natural killer (NK) cell activity in 2 patients with the Chediak-Higashi syndrome (CHS), using both a standard 51-chromium release microcytotoxicity and a single cell-in-agarose assay against K562 and Molt-4 target cells. CHS patients were deficient in overall maximum NK capacity, but had normal percentages of potentially cytotoxic target binding cells. The relative number of TBC that could kill bound targets (i.e., 'active' NK cells) was significantly depressed in CHS patients when compared with normal controls. The diminished CHS active NK cells that were present, however, were capable of recycling and lysing multiple target cells during the assay period. In vitro interferon (INF) treatment of normal and CHS effector cells did not alter target cell binding, but did increase the maximum NK capacity, percentage of active NK cells, and the maximum recycling capacity, as well as the rate of lysis. These studies indicate that the depression of NK activity in patients with CHS is secondary to a deficiency of active NK cells. The CHS active NK cells that are present, however, are capable of normal target lysis and recycling. Potentially cytotoxic pre-NK cells, which can bind but not kill target cells, can be activated by in vitro IFN to develop lytic activity. Thus, IFN treatment may be of potential benefit to the immune surveillance network of CHS patients by activating a population of pre-NK cells to express their cytotoxic potential.

UR - http://www.scopus.com/inward/record.url?scp=0019985228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019985228&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 1231

EP - 1238

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -